Viktor Martyanov - Concepedia

Author

Viktor Martyanov

Dartmouth College ORCID

Also Known As

Martyanov, Viktor, V A Martyanov, V. A. Martyanov, V. A. Mart’yanov, V. Martyanov, Viktor Martyanov, Viktor. Martyanov

110

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Dartmouth College Northwestern University Boston University Cornell University Hospital for Special Surgery

About

Viktor Martyanov is an author at Dartmouth College specializing in medicine, dermatology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	708
2	Cell Biology	4	4	271
3	Immunology	4	4	366
4	Natural Sciences	1	1	33
5	Cellular Physiology	1	1	33

Viktor Martyanov

Publications

1.8K

Citations

H-Index

Page 1

	Year	Citations
Identification of cell cycle–regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors Gavin D. Grant, Lionel Brooks, Xiaoyang Zhang, Molecular Biology of the Cell GeneticsCell CyclePeriodic OscillationsU2os CellsTranscriptional Regulation	2013	181
Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis Monique Hinchcliff, Chiang-Ching Huang, Tammara Wood, Journal of Investigative Dermatology Autoimmune DiseaseSystemic SclerodermaCutaneous BiologyMycophenolate TreatmentImmunology	2013	181
Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms J. Matthew Mahoney, Jaclyn Taroni, Viktor Martyanov, PLoS Computational Biology	2015	146
Belimumab for the Treatment of Early Diffuse Systemic Sclerosis Jessica Gordon, Viktor Martyanov, Jennifer M. Franks, Arthritis & Rheumatology	2017	125
Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis Eliza F. Chakravarty, Viktor Martyanov, David Fiorentino, Arthritis Research & Therapy Autoimmune DiseaseImmunologyClinical TrialsGene Expression ChangesPlacebo-controlled Randomized Trial	2015	115
A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis Jaclyn Taroni, Casey S. Greene, Viktor Martyanov, Genome Medicine	2017	105
Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis Robert Spiera, Laura K. Hummers, Tracy Frech, Arthritis & Rheumatology	2020	101
Myeloid Cells That Impair Immunotherapy Are Restored in Melanomas with Acquired Resistance to BRAF Inhibitors Shannon M. Steinberg, Tamer B. Shabaneh, Peisheng Zhang, Cancer Research	2017	96
Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial Jessica Gordon, Viktor Martyanov, Cynthia M. Magro, Arthritis Research & Therapy Pilot Clinical TrialSystemic SclerodermaMedicineSystemic TreatmentClinical Trials	2015	93
Profibrotic Activation of Human Macrophages in Systemic Sclerosis Rajan Bhandari, Michael Ball, Viktor Martyanov, Arthritis & Rheumatology	2020	85

Page 1